Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of Lubeck
Lubeca, AlemaniaPublicaciones en colaboración con investigadores/as de University of Lubeck (17)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Hepatic p63 regulates glucose metabolism by repressing SIRT1
Gut, Vol. 72, Núm. 3, pp. 472-483
-
Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function
Molecular Metabolism, Vol. 75
-
Interventional Radiotherapy (Brachytherapy) for the Treatment of Primary Lesions in Nasal Vestibule Malignancies
Malignancies of the Nasal Vestibule: A New Perspective on Classification, Staging, and Treatment (Springer International Publishing), pp. 135-144
-
Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism
Cell Metabolism, Vol. 35, Núm. 9, pp. 1630-1645.e5
2021
-
An Experimental DUAL Model of Advanced Liver Damage
Hepatology Communications, Vol. 5, Núm. 6, pp. 1051-1068
-
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Neurology, Vol. 97, Núm. 14, pp. E1367-E1381
-
Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points
Journal of Hepatology
2019
-
Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): Single institution experience and systematic literature review
Journal of Contemporary Brachytherapy, Vol. 11, Núm. 1, pp. 54-60
2018
-
Ent cobra ontology: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy)
Journal of Contemporary Brachytherapy, Vol. 10, Núm. 3, pp. 260-266
-
Treatable inherited rare movement disorders
Movement Disorders, Vol. 33, Núm. 1, pp. 21-35
2016
-
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
Science Translational Medicine, Vol. 8, Núm. 341
-
Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology
Experimental Dermatology, Vol. 25, Núm. 11, pp. 839-846
2007
2005
-
Mucous membrane pemphigoid: IgG and IgA antibodies against the BP180 antigen
Actas Dermo-Sifiliograficas, Vol. 96, Núm. 6, pp. 365-370